References

S-273

CNS Embryonal Tumors and Ependymoma

1. InterQual® Level of Care Criteria, 2021 Acute Care Adult. McKesson Health Solutions, LLC.

2. Raleigh DR, Tomlin B, Del Buono B, et al. Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients. *J Neurooncol.* 2017; 131:359-368.

3. Osario DS, Dunkel IJ, Cervone KA, et al. Tandem thiotepa with autologous hematpoietic cell rescue in patients with recurrent, refractory, or poor prognosis solid tumor malignancies. *Pediatr Blood Cancer.* 2018; 65:e26776.

4. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Central nervous system cancers. Version 2022.

5. National Cancer Institute Physician Data Query (PDQ). Childhood central nervous system embryonal tumors (last modified 3/23/2020). Accessed May 6, 2020.

6. Koo J, Silverman S, Nuechterlein B, et al. Safety and feasibility of outpatient autologous stem cell transplantation in pediatric patients with primary central nervous system tumors. *Bone Marrow Transplant*. 2019;54(10):1605-1613.

7. Osorio DS, Dunkel IJ, Cervone KA, Goyal RK, Steve Lo KM, Finlay JL, Gardner SL. Tandem thiotepa with autologous hematopoietic cell rescue in patients with recurrent, refractory, or poor prognosis solid tumor malignancies. *Pediatr Blood Cancer*. 2018;65(1):10.1002/pbc.26776.

8. Lee JW, Lim DH, Sung KW, et al. Multimodal treatment including tandem high-dose chemotherapy and autologous stem cell transplantation in children with anaplastic ependymomas. *Pediatr Transplant*. 2018;22(3):e13127.

9. Guerra JA, Dhall G, Marachelian A, et al. Marrow-ablative chemotherapy followed by tandem autologous hematopoietic cell transplantation in pediatric patients with malignant brain tumors. *Bone Marrow Transplant*. 2017;52(11):1543-1548.

10. Dufour C, Foulon S, Geoffray A, et al. Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5. *Neuro Oncol*. 2021;23(7):1163-1172.

11. Reddy AT, Strother DR, Judkins AR, et al. Efficacy of high-dose chemotherapy and three-dimensional conformal radiation for atypical teratoid/rhabdoid tumor: A report from the Children's Oncology Group Trial ACNS0333. *J Clin Oncol*. 2020;38(11):1175-1185.

12. Kanate AS, Majhail NS, Savani BN, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant*. 2020;26(7):1247-1256.

Solid Tumors of Childhood

13. Malogolowkin MH, Hemmer MT, Le-Rademacher J, et al. Outcomes following autologous hematopoietic stem cell transplant for patients with relapsed Wilms' tumor: A CIBMTR retrospective analysis. *Bone Marrow Transplant*. 2017:1-7.

14. Khandelwal P, Millard HR, Thiel E, et al. Hematopoietic stem cell transplantation activity in pediatric cancer between 2008 and 2014 in the United States: A center for international blood and marrow transplant research report. *Biol Blood Marrow Transplant*. 2017;23(8):1342-1349.

15. Armstrong AE, Danner-Koptik K, Golden S, et al. Late effects in pediatric high-risk neuroblastoma survivors after intensive induction chemotherapy followed by myeloblative consolidation chemotherapy and triple autologous stem cell transplants. *J Pediatr Hematol Oncol*. 2017:1-5.

16. Atas E, Kutluk MT, Akyuz C. Clinical features and treatment results of children with high-risk neuroblastoma undergone to autologous stem cell transplantation. *Int J Hemato and Oncol*. 2018;3(18);187-196.

17. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bone Cancer. Version 2.2022.

18. Park JR, Kreissman SG, London WB, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: A randomized clinical trial. *JAMA*. 2019;322(8):746-755.

19. Tenneti P, Zahid U, Iftikhar A, et al. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation for children and young adults with relapsed Ewing's sarcoma: A systematic review. *Sarcoma*. 2018:1-12.

20. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Soft tissue sarcoma. Version 2.2022.

21. Uemura S, Mori T, Ishiko S, et al. Retrospective analysis of high-dose chemotherapy followed by autologous stem cell transplantation for high-risk pediatric osteosarcoma. *Pediatr Hematol Oncol*. 2020;37(4):337-343.

22. Giardino S, Piccardo A, Conte M, et al. I-Meta-iodobenzylguanidine followed by busulfan and melphalan and autologous stem cell rescue in high-risk neuroblastoma. *Pediatr Blood Cancer*. 2021;68(2):e28775.

23. Dirksen U, Brennan B, Le Deley MC, et al. High-dose chemotherapy compared with standard chemotherapy and lung radiation in Ewing sarcoma with pulmonary metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. *J Clin Oncol*. 2019;37(34):3192-3202.

24. Delafoy M, Verschuur A, Scheleirmacher G, et al. High-dose chemotherapy followed by autologous stem cell rescue in Wilms tumors: French report on toxicity and efficacy. *Pediatr Blood Cancer*. 2022;69(3):e29431.

Germ Cell Tumors

25. Adra N, Abonour R, Althouse SK, Albany C, Hanna NH, et al. High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: The Indiana University experience. *J Clin Oncol.* 2017;35(10):1096-1102.

26. Lee S, Yamauchi T, Kinoshita K, Imamur S, Kamiya K. High-dose chemotherapy with autologous stem cell transplantation following systemic chemotherapy, prophylactic intrathecal methotrexate, and radiotherapy prevents relapse and improves the outcome of advanced stage primary testicular lymphoma even with cardiac involvement. *J Clin Exp Hematop*. 2017;57(2):64-68.

27. Mousavi SA, Abedinzadeh N, Taj L, et all. Successful outcome of autologous stem cell transplantation for relapsed or refractory germ cell tumors. *Int J Hematol-Oncol Stem Cell Res*. 2018;12(3):191-195.

28. Oing C, Alsdorg W, vonAmsberg G, Oechsle K, Bokemeyer C. Platinum-refractory germ cell tumors: An update on current treatment options and developments. *World J Urol*. 2017;35:1167-1175.

29. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Testicular Cancer. Version 2.2022.

30. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Ovarian Cancer. Version 3.202

31. Zschäbitz S, Distler FA, Krieger B, et al. Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease. 2018;9(32):22537-22545.

32. Agrawal V, Abonour R, Abu Zaid M, et al. Survival outcomes and toxicity in patients 40 years old or older with relapsed metastatic germ cell tumors treated with high-dose chemotherapy and peripheral blood stem cell transplantation. 2021;127(20):3751-3760.

33. Ertürk İ, Yıldız B, Karadurmuş N, et al. Retrospective analysis of patients with relapsed or refractory germ cell tumors treated with autologous hematopoietic stem cell transplantation. *Gulhane Med J*. 2018;60(4):130-135.

34. Kilari D, D'Souza A, Fraser R, et al. Autologous hematopoietic stem cell transplantation for male germ cell tumors: Improved outcomes over 3 decades. *Biol Blood Marrow Transplant*. 2019;25(6):1099-1106.

35. Fergadis E, Gavrielatou N, Skouteris N, Athanasopoulos A, Lianos E, Kosmas C. Myeloablative chemotherapy and autologous stem cell transplantation can lead to successful postengraftment mobilization of hematopoietic progenitors to support planned subsequent cycle(s) of high-dose chemotherapy and autografting in a patient with relapsed germ-cell tumor. *Anticancer Drugs*. 2019;30(2):205-208.

36. Hamid AA, Markt SC, Vicier C, McDermott K, Richardson P, Ho VT, Sweeney CJ. Autologous stem-cell transplantation outcomes for relapsed metastatic germ-cell tumors in the modern era. *Clin Genitourin Cancer*. 2019;17(1):58-64.e1.